Miwa S, Hashikura Y, Mita A, Kubota T, Chisuwa H, Nakazawa Y, Ikegami T, Terada M, Miyagawa S, Kawasaki S
First Department of Surgery, Shinshu University School of Medicine, Matsumoto, Japan.
Hepatology. 1999 Dec;30(6):1521-6. doi: 10.1002/hep.510300621.
The prognosis for patients with fulminant (FHF) or subfulminant hepatic failure (SFHF) has improved since the introduction of liver transplantation. However, the death rate of patients awaiting liver transplantation is high, possibly because of the difficulty in obtaining grafts in a timely manner, given the relative shortage of cadaveric donors. Between June 1990 and June 1999, 106 patients underwent living-related liver transplantation (LRLT) at Shinshu University Hospital. Among them, 8 patients had FHF and 6 had SFHF; these 14 patients are the subjects of this report. The graft volumes (GV) ranged from 231 mL to 625 mL, corresponding to 35% to 105% of the recipients' standard liver volume (SLV). The postoperative courses of all donors were uneventful. Following liver transplantation, all grafts functioned favorably, with normalization of serum total bilirubin within 3 to 5 days and normalization of coagulation profiles within 4 to 7 days. Thirteen of the 14 recipients are still alive. The actuarial 6-month, 1-year, and 5-year survival rates were 100%, 90%, and 90%, respectively. In the present study, when the ratio of the GV to the recipient's SLV was more than 35%, the graft was able to support the patient's metabolic demand after liver transplantation for FHF or SFHF. Because of the urgent nature of liver transplantation in this clinical condition, concerns over informed consent may be even greater than for elective LRLT. Nevertheless, the high success rate and low donor risk may justify this option for pediatric patients, as well as for a limited population of adult patients suffering from FHF or SFHF.
自肝移植引入以来,暴发性肝衰竭(FHF)或亚暴发性肝衰竭(SFHF)患者的预后有所改善。然而,等待肝移植患者的死亡率很高,这可能是由于尸体供体相对短缺,难以及时获得移植物。1990年6月至1999年6月期间,106例患者在信州大学医院接受了活体肝移植(LRLT)。其中,8例为FHF患者,6例为SFHF患者;这14例患者为本报告的研究对象。移植物体积(GV)在231 mL至625 mL之间,相当于受体标准肝体积(SLV)的35%至105%。所有供体的术后过程均顺利。肝移植后,所有移植物功能良好,血清总胆红素在3至5天内恢复正常,凝血指标在4至7天内恢复正常。14例受体中有13例仍存活。6个月、1年和5年的精算生存率分别为100%、90%和90%。在本研究中,当GV与受体SLV的比值超过35%时,移植物能够在肝移植后支持FHF或SFHF患者的代谢需求。由于这种临床情况下肝移植的紧迫性,对知情同意的担忧可能比择期LRLT更大。然而,高成功率和低供体风险可能使这种选择对儿科患者以及有限数量的患有FHF或SFHF的成年患者是合理的。